选择非类固醇抗炎药物在治疗腹症的人
M Hernandez Avila1, A M Walker, I Romieu
1Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Lancet (London, England)
|September 3, 1988
概括
开始使用西米蒂丁的老年患者在治疗前经常使用止痛药,包括NSAID和,在治疗前. 这表明先前止痛药使用与老年人病等疾病之间存在潜在的联系.
科学领域:
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
- 胃肠病学 胃肠病学
背景情况:
- 以前的止痛药的使用在老年人群中很常见.
- 无抗炎药和病之间的关联已经得到了充分证实.
- 降醇在病中的作用不太清楚.
研究的目的:
- 调查65岁及以上的新用户先前使用cimetidine的止痛药的模式.
- 为了比较cimetidine用户和非用户之间的止痛使用.
- 探索止痛药使用与病之间的关联中的潜在混因素.
主要方法:
- 追溯队列研究的设计.
- 对新使用西米提丁的处方数据和对照组的分析.
- 审查关于止痛药使用和病的现有文献.
主要成果:
- 与非使用者 (n=5308) 相比,新使用者 (n=1327) 之前使用的止痛药 (NSAID,阿司匹林,白醇) 显着更高.
- 开始使用西米蒂丁的老年患者更有可能接受最近引入的NSAID.
- 之前的研究表明,尽管缺乏推定因果关系,但使用和病之间存在关联.
结论:
- 以前使用过止痛药,包括青,在老年人中是普遍存在的,是cimetidine发起者.
- 在老年消化不良患者中增加止痛药的使用可能会与病产生人工关联.
- 需要进一步的研究来澄清止痛药的使用,cimetidine和胃肠道结果之间的复杂关系.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...


